A Study of Avutometinib (VS-6766) and Defactinib in People With Mesonephric Gynecologic Cancer

StatusActive, Not Recruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment closed, study ongoing
    • Eligibility criteria expanded, about 40 words
    • Site details revised at 7 of 7 sites
  2. 4 versions Re-verified since Feb 4, 2026, no change to tracked fieldsv15-v18
  3. Primary and study completion dates: Mar 2026 to Mar 2027v14
  4. Re-verified, no change to tracked fieldsv13
  5. Primary and study completion dates: Mar 2025 to Mar 2026
    • Site details revised at 2 of 7 sites
    v12
Show 10 earlier versionsHide 10 earlier versions
  1. Enrollment target: 20 to 40
    • Site details revised at 2 of 7 sites
    v11
  2. Re-verified, no change to tracked fieldsv10
  3. Eligibility criteria expanded, about 14 wordsv9
  4. 6 versions Re-verified since May 26, 2023, no change to tracked fieldsv3-v8
  5. Interventions: Defactinib (Drug), VS-6766 (Drug) to Avutometinib (VS-6766) (Drug), Defactinib (Drug)
    • Study title expanded, about 1 word
    v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study will test if Avutometinib (VS-6766) in combination with Defactinib is an effective treatment for advanced or recurrent mesonephric gynecologic cancer.
Trial Details
NCT Number NCT05787561
Lead Sponsor Memorial Sloan Kettering Cancer Center
Collaborators: Verastem, Inc.
Conditions
(from sponsor)		 Mesonephric Gynecologic Cancer
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov